References
- Bruker Daltonics, Bruker Announces Makor Advances in CCS-Enabled 4D Proteomics at ASMS, 2021, https://www.businesswire.com/news/home/20211102005437/en/Bruker-Announces-Major-Advances-in-CCS-Enabled-4D-Proteomics-at-ASMS
- Damase T.R, The Limitless Future of RNA Therapeutics, Frontiers in Bioengineering and Biotechnology, 2021, https://www.frontiersin.org/articles/10.3389/fbioe.2021.628137/full
- Roberts T.C, Advances in oligonucleotide drug delivery, Nature Reviews Drug Discovery, 2020, https://www.nature.com/articles/s41573-020-0075-7
- Sutton, J.M, et al, Current State of Oligonucleotide Characterization Using Liquid Chromatography-Mass Spectrometry: Insight into Critical Issues, 2020, https://pubs.acs.org/doi/pdf/10.1021/jasms.0c00179#
- Anjali Alving, Bruker Daltonics, Simplifying Oligonucleotide Drug Development Workflows with Mass Spectrometry, 2019, https://www.bruker.com/en/news-and-events/webinars/2019/simplifying-oligonucleotide-drug-development-workflows-with-mass-spectrometry.html
